Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: A nationwide retrospective study

Takashi Ishida, Masakatsu Hishizawa, Koji Kato, Ryuji Tanosaki, Takahiro Fukuda, Shuichi Taniguchi, Tetsuya Eto, Yoshifusa Takatsuka, Yasushi Miyazaki, Yukiyoshi Moriuchi, Michihiro Hidaka, Koichi Akashi, Naokuni Uike, Hisashi Sakamaki, Yasuo Morishima, Ritsuro Suzuki, Takeshi Nishiyama, Atae Utsunomiya

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Adult T-cell leukemia-lymphoma (ATL) is an intractable mature T-cell neoplasm. We performed a nationwide retrospective study of allogeneic hematopoietic stem cell transplantation (HSCT) for ATL in Japan, with special emphasis on the effects of the preconditioning regimen. This is the largest study ofATL patients receiving HSCT. Median overall survival (OS) and 3-year OS of bone marrow or peripheral blood transplantation recipients (n = 586) was 9.9 months (95% confidence interval, 7.4-13.2 months) and 36% (32%-41%), respectively. These values for recipients of myeloablative conditioning (MAC; n = 280) and reduced intensity conditioning (RIC; n = 306) were 9.5 months (6.7-18.0 months) and 39% (33%-45%) and 10.0 months (7.2-14.0 months) and 34% (29%-40%), respectively. Multivariate analysis demonstrated 5 significant variables contributing to poorer OS, namely, older age, male sex, not in complete remission, poor performance status, and transplantation from unrelated donors. Although no significant difference in OS between MAC and RIC was observed, there was a trend indicating that RIC contributed to better OS in older patients. Regarding mortality, RIC was significantly associated with ATL-related mortality compared with MAC. In conclusion, allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL.

Original languageEnglish
Pages (from-to)1734-1741
Number of pages8
JournalBlood
Volume120
Issue number8
DOIs
Publication statusPublished - 2012 Aug 23
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
T-cells
Hematopoietic Stem Cell Transplantation
Stem cells
Retrospective Studies
Survival
Transplantation
Unrelated Donors
Mortality
Japan
Bone
Blood
Multivariate Analysis
Bone Marrow
Confidence Intervals
T-Lymphocytes
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen : A nationwide retrospective study. / Ishida, Takashi; Hishizawa, Masakatsu; Kato, Koji; Tanosaki, Ryuji; Fukuda, Takahiro; Taniguchi, Shuichi; Eto, Tetsuya; Takatsuka, Yoshifusa; Miyazaki, Yasushi; Moriuchi, Yukiyoshi; Hidaka, Michihiro; Akashi, Koichi; Uike, Naokuni; Sakamaki, Hisashi; Morishima, Yasuo; Suzuki, Ritsuro; Nishiyama, Takeshi; Utsunomiya, Atae.

In: Blood, Vol. 120, No. 8, 23.08.2012, p. 1734-1741.

Research output: Contribution to journalArticle

Ishida, T, Hishizawa, M, Kato, K, Tanosaki, R, Fukuda, T, Taniguchi, S, Eto, T, Takatsuka, Y, Miyazaki, Y, Moriuchi, Y, Hidaka, M, Akashi, K, Uike, N, Sakamaki, H, Morishima, Y, Suzuki, R, Nishiyama, T & Utsunomiya, A 2012, 'Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: A nationwide retrospective study', Blood, vol. 120, no. 8, pp. 1734-1741. https://doi.org/10.1182/blood-2012-03-414490
Ishida, Takashi ; Hishizawa, Masakatsu ; Kato, Koji ; Tanosaki, Ryuji ; Fukuda, Takahiro ; Taniguchi, Shuichi ; Eto, Tetsuya ; Takatsuka, Yoshifusa ; Miyazaki, Yasushi ; Moriuchi, Yukiyoshi ; Hidaka, Michihiro ; Akashi, Koichi ; Uike, Naokuni ; Sakamaki, Hisashi ; Morishima, Yasuo ; Suzuki, Ritsuro ; Nishiyama, Takeshi ; Utsunomiya, Atae. / Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen : A nationwide retrospective study. In: Blood. 2012 ; Vol. 120, No. 8. pp. 1734-1741.
@article{3eb6a202711d4070bb0b2973812a57a3,
title = "Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: A nationwide retrospective study",
abstract = "Adult T-cell leukemia-lymphoma (ATL) is an intractable mature T-cell neoplasm. We performed a nationwide retrospective study of allogeneic hematopoietic stem cell transplantation (HSCT) for ATL in Japan, with special emphasis on the effects of the preconditioning regimen. This is the largest study ofATL patients receiving HSCT. Median overall survival (OS) and 3-year OS of bone marrow or peripheral blood transplantation recipients (n = 586) was 9.9 months (95{\%} confidence interval, 7.4-13.2 months) and 36{\%} (32{\%}-41{\%}), respectively. These values for recipients of myeloablative conditioning (MAC; n = 280) and reduced intensity conditioning (RIC; n = 306) were 9.5 months (6.7-18.0 months) and 39{\%} (33{\%}-45{\%}) and 10.0 months (7.2-14.0 months) and 34{\%} (29{\%}-40{\%}), respectively. Multivariate analysis demonstrated 5 significant variables contributing to poorer OS, namely, older age, male sex, not in complete remission, poor performance status, and transplantation from unrelated donors. Although no significant difference in OS between MAC and RIC was observed, there was a trend indicating that RIC contributed to better OS in older patients. Regarding mortality, RIC was significantly associated with ATL-related mortality compared with MAC. In conclusion, allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL.",
author = "Takashi Ishida and Masakatsu Hishizawa and Koji Kato and Ryuji Tanosaki and Takahiro Fukuda and Shuichi Taniguchi and Tetsuya Eto and Yoshifusa Takatsuka and Yasushi Miyazaki and Yukiyoshi Moriuchi and Michihiro Hidaka and Koichi Akashi and Naokuni Uike and Hisashi Sakamaki and Yasuo Morishima and Ritsuro Suzuki and Takeshi Nishiyama and Atae Utsunomiya",
year = "2012",
month = "8",
day = "23",
doi = "10.1182/blood-2012-03-414490",
language = "English",
volume = "120",
pages = "1734--1741",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen

T2 - A nationwide retrospective study

AU - Ishida, Takashi

AU - Hishizawa, Masakatsu

AU - Kato, Koji

AU - Tanosaki, Ryuji

AU - Fukuda, Takahiro

AU - Taniguchi, Shuichi

AU - Eto, Tetsuya

AU - Takatsuka, Yoshifusa

AU - Miyazaki, Yasushi

AU - Moriuchi, Yukiyoshi

AU - Hidaka, Michihiro

AU - Akashi, Koichi

AU - Uike, Naokuni

AU - Sakamaki, Hisashi

AU - Morishima, Yasuo

AU - Suzuki, Ritsuro

AU - Nishiyama, Takeshi

AU - Utsunomiya, Atae

PY - 2012/8/23

Y1 - 2012/8/23

N2 - Adult T-cell leukemia-lymphoma (ATL) is an intractable mature T-cell neoplasm. We performed a nationwide retrospective study of allogeneic hematopoietic stem cell transplantation (HSCT) for ATL in Japan, with special emphasis on the effects of the preconditioning regimen. This is the largest study ofATL patients receiving HSCT. Median overall survival (OS) and 3-year OS of bone marrow or peripheral blood transplantation recipients (n = 586) was 9.9 months (95% confidence interval, 7.4-13.2 months) and 36% (32%-41%), respectively. These values for recipients of myeloablative conditioning (MAC; n = 280) and reduced intensity conditioning (RIC; n = 306) were 9.5 months (6.7-18.0 months) and 39% (33%-45%) and 10.0 months (7.2-14.0 months) and 34% (29%-40%), respectively. Multivariate analysis demonstrated 5 significant variables contributing to poorer OS, namely, older age, male sex, not in complete remission, poor performance status, and transplantation from unrelated donors. Although no significant difference in OS between MAC and RIC was observed, there was a trend indicating that RIC contributed to better OS in older patients. Regarding mortality, RIC was significantly associated with ATL-related mortality compared with MAC. In conclusion, allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL.

AB - Adult T-cell leukemia-lymphoma (ATL) is an intractable mature T-cell neoplasm. We performed a nationwide retrospective study of allogeneic hematopoietic stem cell transplantation (HSCT) for ATL in Japan, with special emphasis on the effects of the preconditioning regimen. This is the largest study ofATL patients receiving HSCT. Median overall survival (OS) and 3-year OS of bone marrow or peripheral blood transplantation recipients (n = 586) was 9.9 months (95% confidence interval, 7.4-13.2 months) and 36% (32%-41%), respectively. These values for recipients of myeloablative conditioning (MAC; n = 280) and reduced intensity conditioning (RIC; n = 306) were 9.5 months (6.7-18.0 months) and 39% (33%-45%) and 10.0 months (7.2-14.0 months) and 34% (29%-40%), respectively. Multivariate analysis demonstrated 5 significant variables contributing to poorer OS, namely, older age, male sex, not in complete remission, poor performance status, and transplantation from unrelated donors. Although no significant difference in OS between MAC and RIC was observed, there was a trend indicating that RIC contributed to better OS in older patients. Regarding mortality, RIC was significantly associated with ATL-related mortality compared with MAC. In conclusion, allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL.

UR - http://www.scopus.com/inward/record.url?scp=84865441105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865441105&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-03-414490

DO - 10.1182/blood-2012-03-414490

M3 - Article

C2 - 22689862

AN - SCOPUS:84865441105

VL - 120

SP - 1734

EP - 1741

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -